Under the contract, Cytovance will develop FB301 at its process development and analytical laboratories and manufacture at its 44,000ft² production facility.
In addition, Cytovance will spearhead the cell line generation, cell culture process optimization, recovery and purification development, cGMP manufacturing as well as technical and regulatory support to facilitate Fountain’s clinical program.
Fountain BioPharma president Willie Lin said, "The FB301 antibody is Fountain’s flagship product, which represents a new, innovative medicine to treat a vast array of IgE-mediated allergic diseases; FB301 is licensed from Academia Sinica, the internationally renowned and most prestigious research institute in Taiwan."
Cytovance Biologics president and chief executive officer Darren Head said the company is excited that Fountain has chosen it to support its clinical program.
"We have successfully completed several development and manufacturing service agreements with Asian clients in the past two years and are actively expanding our services to the Asian Pacific region, led by Dr. Jeffrey Su, our Chief Scientific Officer," Head added.